Drug intelligence / Profile preview

GSK3003895A

Development stage: Unknown
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

GSK3003895A is an investigational vaccine candidate developed by GSK (GlaxoSmithKline) Biologicals for the prevention of respiratory syncytial virus (RSV) infection. It is a protein-based vaccine administered intramuscularly and has been evaluated in Phase 2 clinical trials in healthy adults aged 18 to 45 years. The primary aim of these studies was to assess safety, reactogenicity, and immunogenicity. RSV is a major cause of lower respiratory tract infections, particularly in infants and older adults. The mechanism of action for this vaccine involves stimulating an immune response against respiratory syncytial virus antigen to provide protective immunity[4][8].

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on GSK3003895A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3003895A.

Explore the full profile